BuserelinHormone TherapySafety Rating 8/10
Primary research areaProstate cancer
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range300-900 mcg intranasal; 0.5-2 mg SC
AdministrationNasal or subcutaneous injection
Safety8/10 · Approved (various countries)
NCAA D1Banned
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Buserelin
Mechanism of action
GnRH agonist; nasal or injectable formulations
Safety profile
Hot flashes, sexual dysfunction, bone density loss · Approved for prostate cancer, endometriosis; hot flashes, bone loss with long-term use; well-established
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Buserelin below your target.
Related pages